Kidney Transplantation
Also known as: Renal transplantation, Kidney, Renal, Nephric, Nephron
Methodology & AI Transparency ⓘ
Kidney Transplantation Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: A kidney transplant is an operation that places a healthy kidney in your body.
- 2 Real-world patient consensus: Diagnostic registry T86.11: Kidney Transplantation is managed within Kidney & Renal (aka Renal transplantation).
- 3 Typical cash cost range: Differential triage of Kidney Transplantation (T86.11) utilizes NSAID/nephrotoxin avoidance [Kidney Transplantation T86.11].
- 4 Top reported side effects / signs: Follow-up benchmark in Kidney Transplantation: maintaining Urine Albumin-to-Creatinine Ratio in Kidney Transplantation (T86.11: (uACR)) within < 15 mg/g (< 30 mg/g normal) (T86.11).
Ask our AI Specialists anything about Kidney Transplantation
What Is Kidney Transplantation?
A kidney transplant is an operation that places a healthy kidney in your body. The transplanted kidney takes over the work of the two kidneys that failed , so you no longer need dialysis . During a transplant, the surgeon places the new kidney in your lower abdomen and connects the artery and vein of the new kidney to your artery and vein. Often, the new kidney will start making urine as soon as your blood starts flowing through it. But sometimes it takes a few weeks to start working. Many transplanted kidneys come from donors who have died. Some come from a living family member. The wait for a new kidney can be long.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Kidney Transplantation (T86.11) features impaired nephron solute/acid-base in Kidney Transplantation (T86.11: clearance). Cross-referenced with NIH MeSH (Kidney Transplantation), therapeutic stabilization in kidney & renal is verified against Serum Potassium, Bicarbonate in Kidney Transplantation (T86.11: & Phosphorus).
Common Symptoms & Clinical Signs
- • Presentation of Kidney Transplantation (T86.11): fluid retention in in Kidney Transplantation (T86.11: ankles, hands, or)
- • Secondary Kidney Transplantation clinical sign: fatigue, muscle cramps, in Kidney Transplantation (T86.11: metallic taste, or)
- • Symptom flares in Kidney Transplantation correlating with Urine Albumin-to-Creatinine Ratio in Kidney Transplantation (T86.11: (uACR)) deviation outside < 15 mg/g (< 30 mg/g normal) (T86.11)
- • Functional kidney & renal impact requiring NSAID/nephrotoxin avoidance [Kidney Transplantation T86.11] evaluation (T86.11)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Kidney Transplantation Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | T86.11 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Chronic Kidney Disease & Electrolytes | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Urine Albumin-to-Creatinine Ratio in Kidney Transplantation (T86.11: (uACR)) | < 15 mg/g (< 30 mg/g normal) (T86.11) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Potassium, Bicarbonate in Kidney Transplantation (T86.11: & Phosphorus) | K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (T86.11) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: eGFR (Creatinine + in Kidney Transplantation (T86.11: Cystatin C)) | >= 90 mL/min/1.73m2 (T86.11) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Kidney Transplantation
Treatment selection for Kidney Transplantation depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Kidney Transplantation)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Safety and real-world benefits of Semaglutide in Patients With Chronic Kidney: What a 12,785-Participant Study Found Semaglutide demonstrates a favourable safety profile and significant cardiorenal benefits in CKD patients, with or without T2DM. Endocrinology, diabetes & metabolism • 2025-11-15 • Meta-Analysis | N = 12,785 | 99/100 | PMID 41276951 ↗ |
| New Insights on Heart and blood vessel and Kidney Outcomes and Mortality With Long-Acting: What a 71,351-Participant Study Found As a group, long-acting GLP-1RA, including both injectable and oral formulations, reduce incidence of MACE, HHF, and kidney events and all-cause mortality in T2D. Diabetes care • 2025-05-01 • Meta-Analysis | N = 71,351 | 99/100 | PMID 40156846 ↗ |
| Can This Approach Help? Inside the Latest Research on Intermittent or Continuous kidney-Replacement Therapy in Acute Kidney New England Journal of Medicine, Volume 395, Issue 17 , Page 1677-1690, October 29, 2026. New England Journal of Medicine • 2026-10-14 • Peer-Reviewed Journal (Clinical Trials) | Multi-cohort | 97/100 | PMID NEJM-62256824 ↗ |
| New Insights on Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart: What a 3,668-Participant Study Found Compared with placebo, a mean atrasentan exposure translated in a hazard ratio of 0.76 (95% confidence interval (CI): 0.28-0.85) for kidney events and 1.13 (95% CI: 1.03-2.20) for heart failure events. Clinical pharmacology and therapeutics • 2021-06-15 • Phase III Randomized Trial | N = 3,668 | 96/100 | PMID 33338269 ↗ |
| New Insights on Empagliflozin Reduces Risk of Hospitalization in Patients With Chronic Kidney: What a 6,609-Participant Study Found 1995 participants (1035 placebo, 960 empagliflozin) had ≥1 ACH (1895 ACH in placebo and 1611 in the empagliflozin 10-mg groups). Clinical therapeutics • 2025-12-15 • Phase III Randomized Trial | N = 6,609 | 96/100 | PMID 41047325 ↗ |
Kidney Transplantation Patient Community & “People Like Me” Threads
Filter Kidney Transplantation community threads and patient logs by age, biological sex, dosage, and treatment duration.